Chapter 9. Flavones and Xanthenones as Vascular-disrupting Agents

  1. Dietmar W. Siemann3,4
  1. Bronwyn G. Siim1,2 and
  2. Bruce C. Baguley1,2

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch9

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

How to Cite

Siim, B. G. and Baguley, B. C. (2006) Flavones and Xanthenones as Vascular-disrupting Agents, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch9

Editor Information

  1. 3

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 4

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. 1

    Department of Molecular Medicine and Pathology, The University of Auckland, Private Bag 92019, 85 Park Road, Grafton, Auckland, New Zealand

  2. 2

    Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, 85 Park Road, Grafton, Auckland, New Zealand

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436

SEARCH

Keywords:

  • flavones and xanthenones as vascular-disrupting agents;
  • DMXAA and FAA - vascular shutdown;
  • antivascular activity of FAA and DMXAA;
  • molecular target;
  • combination treatments;
  • DMXAA and radioimmunotherapy;
  • DMXAA and photodynamic therapy;
  • serotonin and DMXAA dose

Summary

This chapter contains sections titled:

  • Development of FAA and DMXAA

  • Antivascular activity of FAA and DMXAA

  • Cytokine induction by FAA and DMXAA

  • Molecular target

  • Preclinical studies: DMXAA as a single agent

  • Preclinical studies: combination treatments

  • Species differences

  • Clinical studies

  • References